Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.Le texte complet de cet article est disponible en PDF.
Key words : biologic agents, clinical guidelines for psoriasis, dermatology, guidelines, monoclonal antibodies, psoriasis, skin disease
Abbreviations used : AAD, BSA, FDA, HAART, IBD, IL, m-PPPASI, NAPSI, NB-UVB, NPF, PASI, PASI 75, PASI 90, PASI 100, PPPASI, PsA, PSSI, QOL, RCT, SCC, WG
| Funding sources: None.
| American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The American Academy of Dermatology conflict of interest policy summary may be viewed at www.aad.org. The conflicts of interest of the individual working group members are listed in the text of this guideline.
| Reprints not available from the authors.